Ocugen to discuss gene therapy data

Ocugen, Inc. will host a webcast to present Phase 2 clinical trial data for OCU410, a gene therapy candidate for geographic atrophy. The presentation, scheduled for March 24, will provide insights into the efficacy and safety of this innovative treatment for a severe form of vision loss. This update is crucial for investors and the medical community, offering a glimpse into the potential of Ocugen's gene therapy platform. Positive data could significantly advance the development of OCU410 towards regulatory approval and future commercialization.